EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration

Inka Pirinen, Sanna Leinonen, Mika Helminen, Pekko Hujanen, Anu Vaajanen iD, Anja Tuulonen iD, Hannele Uusitalo-Järvinen iD

Acta Ophthalmologica · 2023-05 · 101 (3) · 261-265

DOI: 10.1111/aos.15288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 17.11.2022. Verfasst von Inka Pirinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tays Eye Centre, Tampere University Hospital, Tampere, Finland. Hauptthemen laut MEDLINE: Glaucoma, Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Competitive Research Funding of the Pirkanmaa Hospital District, LUX - foundation for glaucoma research, Silmäsäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to investigate how often glaucoma and neovascular age‐related macular degeneration (nAMD) occur in the same patient and to evaluate whether glaucoma progression is faster in eyes treated with intravitreal anti‐VEGF medications for nAMD.

Methods

This single‐centre retrospective real‐world data (RWD) consists of medical records of 6314 glaucoma and 2166 nAMD patients treated in 2008–2017 in Tays Eye Centre, Finland. To study glaucoma progression, changes in visual fields (mean deviation [MD], dB/year), IOP (mmHg/year) and fundus photographs (progression, yes/no) were compared in glaucoma eyes with and without anti‐VEGF treatment for nAMD and ≥1 year follow‐up.

Results

During the 10‐year period, 147 patients with glaucoma received intravitreal anti‐VEGF treatment for nAMD corresponding to 2% of glaucoma and 7% of nAMD patients. The mean change in MD was −0.70 dB/year (SD 1.8) vs. −0.27 dB/year (SD 1.7) ( p = 0.027) in glaucoma eyes with ( n = 37) and without ( n = 4304) anti‐VEGF injections, respectively. In patients with bilateral glaucoma and unilateral nAMD treated with anti‐VEGF injections ( n = 20), MD declined at −0.62 dB/year (SD 1.9) vs 0.33 dB/year (SD 1.5) ( p = 0.654), and glaucoma progression was detected in 14/20 vs 10/20 ( p = 0.219) fundus photographs in eyes with anti‐VEGF treatment compared with their untreated fellow eyes. Conclusion nAMD and glaucoma were found co‐existing in the same eye at rates that were similar to the age‐corrected prevalence of the two diseases in the general population. Our results suggest that intravitreal anti‐VEGF treatment for nAMD may accelerate glaucoma progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaMacular DegenerationHumansAngiogenesis InhibitorsFollow-Up StudiesRetrospective StudiesVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

AMDanti-VEGF injectionsglaucoma progressionreal-world data

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Tays Eye Centre, Tampere University Hospital, Tampere, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Faculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland.
  • Tays Research Services, Tampere University Hospital, Tampere, Finland.
  • Health Center Mehilainen, Helsinki, Finland.
  • Health Center Terveystalo, Tampere, Finland.

ORCID-Profile: Anu Vaajanen, Anja Tuulonen, Hannele Uusitalo-Järvinen

Förderung

  • Competitive Research Funding of the Pirkanmaa Hospital District
  • LUX - foundation for glaucoma research
  • Silmäsäätiö
  • Pirkanmaa Hospital District
  • Finnish Eye Foundation
  • Tampere University Hospital
  • Pirkanmaan Sairaanhoitopiiri
  • Tays

Zitieren

APA

Pirinen, I., Leinonen, S., Helminen, M., Hujanen, P., Vaajanen, A., Tuulonen, A., & Uusitalo-Järvinen, H. (2023). Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration. Acta Ophthalmologica, 101(3), 261-265. https://doi.org/10.1111/aos.15288

Vancouver

Pirinen I, Leinonen S, Helminen M, Hujanen P, Vaajanen A, Tuulonen A, et al. Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration. Acta Ophthalmologica. 2023;101(3):261-265. doi:10.1111/aos.15288

BibTeX
@article{Pirinen2023,
  author = {Pirinen, Inka and Leinonen, Sanna and Helminen, Mika and Hujanen, Pekko and Vaajanen, Anu and Tuulonen, Anja and Uusitalo-Järvinen, Hannele},
  title = {Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration},
  journal = {Acta Ophthalmologica},
  year = {2023},
  volume = {101},
  number = {3},
  pages = {261--265},
  doi = {10.1111/aos.15288}
}
Kostenlos starten →